Subscribe to RSS
DOI: 10.1055/s-0040-1704620
ACCEPTABILITY OF KEY PERFORMANCE INDICATORS (KPI) IN THE NATIONAL ENDOSCOPY DATABASE (NED) AUTOMATED PERFORMANCE REPORTS TO IMPROVE QUALITY OUTCOMES TRIAL (APRIQOT), A DELPHI PROCESS
Publication History
Publication Date:
23 April 2020 (online)
Aims APRIQOT uses NED to provide endoscopists feedback on colonic detection KPI. Traditional adenoma detection rate is dependent on unavailable histological data. Our aim was to gain expert consensus on which available KPI are acceptable to endoscopists.
Methods A Delphi panel of UK expert endoscopists was recruited online, purposively sampling to match clinical background to census data.
Panellists interacted using an online form. In round one we provided a summary and acceptability statement for each KPI, participants rated agreement with a five-point Likert scale and free-text comments. Responses were analysed anonymously. In subsequent rounds participants reviewed all graded consensus statements and comments. Statements were accepted with ≥80% consensus (Agree and Strongly Agree) or redrafted. HRA ethical approval was granted within APRIQOT. Rounds ran January to April 2019.
Results
We recruited 21 UK expert endoscopists. Twelve were female, 48% gastroenterology background, 29% nursing, 14% surgical and 9% trainees. All statements reached consensus after three rounds.
The panel agreed that each KPI may be adjusted for polyp associated ‘case mix’ variables, such as indication, making KPI ‘more acceptable’. Benefits of encompassing non-adenomatous polyps were highlighted versus ‘gaming’ and distal hyperplastic polyp over-reporting.
Mean number of polyps (MNP) reached consensus after discussing reduction of the ‘one and done’ phenomenon and using a cap of five polyps/colon to mitigate skew from polyposis.
Proximal polypectomy rate (PPR) was accepted as a secondary ‘tool to improve right sided … detection’ and could reduce ‘gaming’, despite concerns around contraindications to polypectomy and endoscopists polypectomy skills.
Conclusions All adjusted KPI were accepted, MNP was selected for trial with robust data to model case-mix.
#